Malakar S, Giri S, Jena A, Nath P. Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(1): 112788 [DOI: 10.4292/wjgpt.v17.i1.112788]
Corresponding Author of This Article
Suprabhat Giri, Associate Professor, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5, KIIT Road, Patia, Bhubaneswar 751024, Odisha, India. supg19167@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mar 5, 2026 (publication date) through Feb 11, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Malakar S, Giri S, Jena A, Nath P. Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(1): 112788 [DOI: 10.4292/wjgpt.v17.i1.112788]
Sayan Malakar, Department of Gastroenterology, King George Medical University, Lucknow 226003, Uttar Pradesh, India
Suprabhat Giri, Preetam Nath, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, Odisha, India
Anuraag Jena, Department of Gastroenterology, IMS and SUM Hospital, Bhubaneshwar 751029, Odisha, India
Author contributions: Giri S and Jena A contributed to the conception and design of the manuscript; Malakar S, Giri S, Jena A, and Nath P contributed to the literature review, analysis, data collection, interpretation, and the critical revision of the initial manuscript; Malakar S and Giri S drafted the initial manuscript; All the authors approved the final version of the manuscript.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Suprabhat Giri, Associate Professor, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5, KIIT Road, Patia, Bhubaneswar 751024, Odisha, India. supg19167@gmail.com
Received: August 7, 2025 Revised: September 1, 2025 Accepted: November 24, 2025 Published online: March 5, 2026 Processing time: 189 Days and 1.4 Hours
Core Tip
Core Tip: Janus kinase inhibitors are reserved for moderate-to-severe inflammatory bowel disease (IBD) after biologic failure or steroid dependence. Carefully selecting patients based on their cardiovascular, thromboembolic, and infection-related risks is of paramount importance. Tofacitinib is an excellent choice for patients with moderate to severe ulcerative colitis (UC) and acute severe UC. Upadacitinib is currently approved for both refractory UC and Crohn’s disease (CD); however, emerging data suggest its beneficial role in acute severe UC. Limited evidence exists for the combination of small molecules and other biologicals in patients with difficult-to-treat IBD and peri-anal CD. Close monitoring of side effects is advocated in such patients. More data is warranted on their role in extraintestinal manifestations, pediatric and pregnant patients with IBD.
